1. Home
  2. VERI vs SGMT Comparison

VERI vs SGMT Comparison

Compare VERI & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veritone Inc.

VERI

Veritone Inc.

HOLD

Current Price

$1.31

Market Cap

142.2M

Sector

Technology

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$7.46

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
VERI
SGMT
Founded
2014
2006
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
142.2M
169.4M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
VERI
SGMT
Price
$1.31
$7.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
8
Target Price
$7.00
$26.13
AVG Volume (30 Days)
2.8M
1.2M
Earning Date
04-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$92,637,000.00
$2,000,000.00
Revenue This Year
$52.20
N/A
Revenue Next Year
$3.06
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.27
$4.50
52 Week High
$9.42
$11.41

Technical Indicators

Market Signals
Indicator
VERI
SGMT
Relative Strength Index (RSI) 34.56 58.68
Support Level N/A $7.09
Resistance Level $2.35 $8.80
Average True Range (ATR) 0.12 0.39
MACD 0.01 0.10
Stochastic Oscillator 9.21 71.05

Price Performance

Historical Comparison
VERI
SGMT

About VERI Veritone Inc.

Veritone Inc is a provider of artificial intelligence (AI) computing solutions and services. It generates revenue through the delivery of its Software Products and Services which consists of revenues generated from Commercial Enterprise and Government and Regulated Industries customers using the company's aiWARE platform and hiring solutions, any related support and maintenance services, and any related professional services associated with the deployment and/or implementation of such solutions, Managed Services which consist of revenues generated from Commercial Enterprise customers using company's content licensing services, advertising agency, influencer management and related services. It has presence in the United States, the United Kingdom, France, Australia, Israel, and India.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: